A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like Ozempic and Wegovy. In phase III trials it significantly lowered blood sugar ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

Cheaper alternatives to popular weight loss drugs are flooding the market — but experts are sounding the alarm. A crackdown on cheaper weight loss drugs is leading some Americans toward risky ...

Its own injectable peptide, semaglutide, which is the active ingredient in both Ozempic and Wegovy ... being a viable alternative to Novo's Ozempic and even the company's own drugs Zepbound ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any anti-diabetic medication and have been managing their condition through diet and ...